Sunrise, FL – November 9, 2016 – U.S. STEM CELL, INC., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies to human and animal patients, is pleased to highlight the following results from operations for the quarter ending September 30, 2016:
• Current liabilities down $734,000 or 9.5% from $7.69M in Q3 2015 to $6.96M in Q3 2016
• Revenue up by 31% to from $557,000 in Q3 2015 to $729,000 in Q3 2016
• Net loss improved 17% from $264,000 in Q3 2015 to $219,000 in Q3 2016
• Cash used in operating activities down $322,000 or 84% from $384,000 in Q3 2015 to $62,000 in Q3 2016
“U.S. Stem Cell, Inc. continues to surpass its quarter-over-quarter business and financial performance,” stated Mike Tomas, President and CEO of U.S. Stem Cell Inc. “This is our best year yet so far. We have become a world leader in the research of new treatments for patients with degenerative conditions and continue to develop novel protocols for their care. This passion moves us to continue to work hard to strengthen the health of our business and expand our care to more countries and more patients in need.”
Operating results for the three and six months ended September 30, 2016 are not necessarily indicative of the results that can be expected for the year ending December 31, 2016.
About U.S. Stem Cell, Inc.
US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.
Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.